Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study

• DOI: 10.1186/s12967-022-03857-y
• Publication Date: 2023-01-09T09:03:49Z
• Authors: Bolun Zhou; Ruochuan Zang; Peng Song; Moyan Zhang; Fenglong Bie; Guangyu Bai; Yuan Li; Qilin Huai; Yuning Han; Shugeng Gao
• Keywords: Cumulative incidence

The most common form of treatment for non-metastatic lung cancer is surgery-based combination therapy, which may also include adjuvant radiotherapy or chemotherapy. Second primary malignancies (SPMs) are uncommon but significant radiation side effects in patients with resectable cancer, and SPMs have not been adequately investigated. Our study aims to assess the correlations development cancer.We screened any malignancy that occurred more than five years after diagnosis cancer. Based on large cohort Surveillance, Epidemiology End Results database, radiotherapy-correlated risks were estimated using Poisson regression analysis cumulative incidence was calculated Fine-Gray competing risk analysis.Among 62,435 undergoing surgery, a total 11,341 (18.16%) received radiotherapy. findings indicated substantially related high main second solid (RR = 1.21; 95%CI, 1.08 1.35) negligible hematologic 1.08; 0.84 1.37). With greatest number patients, acquiring gastrointestinal highest overall 1.77; 95 percent CI, 1.44 2.15). standardized ratios revealed similar findings. Furthermore, young elderly be vulnerable, seen ten diagnosis. Additionally, attention should paid individuals cancer.After receiving radiotherapy, an increased developing cancers observed prevention associated requires further attention.